Type: Oral
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research, Health outcomes research, Real-world evidence, Treatment Considerations, Biological therapies, Registries, Survivorship, Study Population, Human, Transplantation (Allogeneic and Autologous)
Methods: Leveraging recent comprehensive immunopeptidomics data (Racle et al, Immunity 2023; Gfeller et al, Cell Systems 2023), we updated our previous PBM classification to include 2,488 HLA class I as well as 381 HLA-DR allotypes, for a total of 29 PBM groups. The cumulative number (0-4) of PBM mismatches in the graft-versus-host direction (PBM-GvH) at HLA-A, -B, -C, -DRB1 on the unshared haplotype was calculated in a cohort of 3,429 haploidentical donor-recipient pairs collected by the CIBMTR. Patients had received haploidentical HCT under post-transplantion-cyclophosphamide (PTCy)-based graft-versus-host disease (GvHD) prophylaxis between 2014 and 2020, for the treatment of acute leukemia or myelodysplastic neoplasms. A cohort of 1,451 HLA-A, -B, -C, -DRB1 (8/8) matched unrelated PTCy-based HCT was used as reference (i.e., 0 PBM mismatches). Multivariate Cox-proportional hazards models and adjusted Kaplan-Meier curves were used for testing the number of PBM mismatches with overall survival (OS) as the primary endpoint.
Results: PBM groups could be assigned to both alleles at all 4 HLA loci of interest for patient and donor in 2,198/3,429 (64.1%) haploidentical pairs. Of these, 48 (2%), 304 (14%), 702 (32%), 805 (37%) and 339 (15%) had 0, 1, 2, 3 or 4 PBM-GvH mismatches, respectively. In multivariate analysis, OS appeared worse after haploidentical HCT in all 4 PBM-GvH mismatch groups compared to the 8/8 matched unrelated HCT reference. However, this association was most pronounced for haploidentical transplants across a single PBM-GvH mismatch (Hazard ratio [HR] 1.42, 95% Confidence Interval [CI] 1.19-1.69, p=0.0001), and less so for haploidentical HCT across multiple PBM-GvH mismatches (HR 1.18, 95% CI 0.99-1.41, p=0.06 for 4 PBM-GvH mismatches, similar data for 3 or 2 PBM-GvH mismatches). Mortality risks were similarly worse when the single PBM-GvH mismatch was in HLA class I (HR 1.42, 95% CI 1.17-1.72, p=0.0003) or HLA-DRB1 (HR 1.44, 95% CI 1.02-2.02, p=0.04), independently from the number of HLA allele mismatches. The effects on OS were mirrored by a trend for lower leukemia-free survival (HR 1.21, 95% CI 1.03-1.43, p=0.02) and higher relapse (HR 1.29, 95% CI 1.06-1.58, p=0.01) for the single PBM-GvH mismatch group compared to the reference. No significant associations were observed for acute GvHD 3-4 (HR 0.70, 95% CI 0.38-1.27, p=0.24) or transplant-related mortality (HR 1.22, 95% CI 0.79-1.87, p=0.37).
Conclusion: The cumulative immunopeptidome divergence between mismatched HLA on the unshared haplotype, as proxied by the number of PBM-GvH mismatches, informs survival probabilities after haploidentical HCT with PTCy. Single PBM-GvH mismatches are associated with worse survival than multiple PBM-GvH mismatches, possibly due to higher relapse incidence. Mechanistically, this might suggest a higher threshold of allogeneic stimuli (i.e., a higher number of immunogenic mismatches) needed for optimal T-cell mediated graft-versus-leukemia activity in PTCy-based HCT protocols. Prioritization of PBM-GvH mismatched donors for patients with hematological malignancies could potentially improve outcome of haploidentical HCT.
Disclosures: Lee: AstraZeneca: Research Funding; Incyte: Honoraria, Research Funding; Pfizer: Research Funding; Sanofi: Honoraria, Research Funding; Novartis: Honoraria; Janssen: Research Funding; NMDP: Membership on an entity's Board of Directors or advisory committees.